| DC22503 |
Val-Cit-PAB-MMAE
Featured
|
A drug-linker conjugate for Antibody-drug conjugates (ADCs) by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide Val-Cit-PAB.. |
|
| DC8539 |
DM1-SMCC
Featured
|
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. |
|
| DC10120 |
MC-Val-Cit-PAB
Featured
|
MC-Val-Cit-PAB, also known as MC-Val-Cit-PAB-OH, is a cathepsin cleavable ADC peptide linker. MC-Val-Cit-PAB is useful for making ADC conjugate (antibody-drug conjugate). FDA approved drugs such as brentuximab vedotin used this linker. |
|
| DC10159 |
N3-PEG3-vc-PAB-MMAE
Featured
|
N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB. |
|
| DC11013 |
Tesirine
Featured
|
Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload. |
|
| DC28508 |
SC-VC-PAB-MMAE |
SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB. |
|
| DC28509 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. |
|
| DC28510 |
DBCO-PEG4-VC-PAB-DMEA-PNU-159682 |
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. |
|
| DC28685 |
Thalidomide-NH-PEG7 |
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader. |
|
| DC28907 |
MMAE-SMCC |
MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate. |
|
| DC31389 |
SGD-1269(MCMMAF)
Featured
|
Mafodotin, also known as mc-MMAF and SGD-1269 or Maleimidocaproyl monomethylauristatin F, is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful a |
|
| DC40402 |
MAC glucuronide α-hydroxy lactone-linked SN-38 |
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 99 and 105 ng/mL, respectively. |
|
| DC40468 |
Mc-VC-PAB-SN38
Featured
|
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC40590 |
DBCO-PEG4-MMAF
Featured
|
DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. |
.gif)
|
| DC40875 |
MC-DM1
Featured
|
MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC). |
|
| DC40876 |
Mc-Dexamethasone |
Mc-Dexamethasone is a drug-linker conjugate for ADC. Mc-Dexamethasone is made toxin Dexamethasone conjugated to the non-cleavable MC linker. Dexamethasone is a?glucocorticoid receptor?agonist. |
|
| DC42455 |
Acetylene-linker-Val-Cit-PABC-MMAE |
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC. |
|
| DC45852 |
Lys-Nε-SPDB-DM4 |
Lys-Nε-SPDB-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC). |
|
| DC46006 |
Modified MMAF-C5-COOH |
Modified MMAF-C5-COOH is a drug-linker conjugate for ADC. |
|
| DC46087 |
MCC-DM1 |
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1. |
|
| DC46088 |
Ozogamicin |
Ozogamicin is a drug-linker conjugates for ADC. Ozogamicin can used in the synthesis of gemtuzumab ozogamicin and inotuzumab ozogamicin. |
|
| DC46199 |
DBCO-PEG4-Ahx-DM1
Featured
|
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. |
|
| DC46201 |
MC-VC-PABC-SP 141 |
MC-VC-PABC-SP 141 is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC. |
|
| DC46202 |
N3-PEG4-DYKDDDD-Doxorubicin |
N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD. |
|
| DC46203 |
N3-PEG4-YPYDVPDYA-Doxorubicin |
N3-PEG4-YPYDVPDYA-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-YPYDVPDYA. |
|
| DC46204 |
N3-PEG8-Phe-Lys-PABC-Gefitinib |
N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. |
|
| DC46211 |
FCHFHS-ST7612AA1 |
FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
|
| DC46212 |
MAC-VC-PABC-ST7612AA1 |
MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
|
| DC46213 |
OSu-PEG4-VC-PAB-Duocarmycin SA |
SA is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin SA (a potent DNA alkylation activator), linked via the cleavable ADC linker OSu-PEG4-VC-PAB. |
|
| DC46214 |
Sulfo-SPDB-DGN462 |
Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
|
|
